Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, parallel-arm, Phase 3 study designed
to compare efficacy, safety, immunogenicity, and PK of BAT2306 with Cosentyx in patients with
moderate to severe plaque psoriasis.
The study is composed of a ≤ 28-day screening period, a 24-week initial treatment period
(Treatment Period 1 [TP1]), and a 28-week secondary treatment period (Treatment Period 2
[TP2]). The study will be a maximum of 56 weeks.